

**Express Mail No. EK968023021**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of  
Frederick M. Enright *et al.*

Group 1653  
Examiner Lukton, D.

Serial No. 10/\_\_\_\_\_

Filed: July 11, 2003

For: Ligand/Lytic Peptide Compositions and Methods of Use (File 96A3.3 Enright)

M.S. Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT**

Please amend the specification and Claims as shown in Appendices A and B, respectively.

**REMARKS**

The specification has been amended at page 1 to update the cross-references to the several priority applications.

The Claims have been amended in various ways, as shown in Appendix B. Rather than lengthen this paper with detailed explanations of each and every amendment to each and every claim, it seems simpler to describe each of the different types of amendments that have been made to the Claims. On the other hand, if the Office would prefer a more detailed explanation for each Claim, the undersigned would be happy to prepare such an explanation on request.

Several Claims have been canceled. Each claim amendment shown in Appendix B falls into one or more of the following categories: